Get a glimpse into our company and investor data—powered by the PitchBook Platform
M&ALATEST DEAL TYPE
$645MLATEST DEAL AMOUNT
Developer of gene therapies for the treatment of monogenic disorders. The company specializes in developing therapeutic reagents to diagnose diseases related to central nervous system and neuromuscular conditions.